Verdict at a Glance Tirzepatide is the proven choice with FDA approval and extensive clinical data
However, as we mentioned taking glutathione can be expensive, lead to side effects, and could have an impact on the production of glutathione
It's rarely asked for, but it takes minutes to prepare and can smooth things over if anything gets flagged
Biopharma companies face: Massive competition and potential market saturation with over 500 GLP-1-related clinical trials across 100+ indications Downward price pressure Highly restricted reimbursement and resistance to new indications Mechanism-based stratification can: Enrich clinical trials for responders (response biomarkers) Identify strong responder subgroups (complementary diagnostic) Differentiate competing assets Support development in new indications (biomarker-led indication switching) De-risk late-stage programs (clinical trial design) Past efforts to expand GLP-1s into new indications - such as the semaglutide Alzheimers trial - largely targeted broad patient groups defined by their clinical symptoms or diagnostic labels
13:465 (2023) Baudouin-Cornu P, Lagniel G, Kumar C, Huang ME, Labarre J
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
